Research Article
The Predictive Effectiveness of Blood Biochemical Indexes for the Severity of COVID-19
Table 1
Baseline characteristics and laboratory findings of patients infected with 2019-nCoV on admission to hospital.
| | All patients (n = 108) | Disease severity | | Severe (n = 24) | Nonsevere (n = 84) |
| | Age | | Median, year | 43.61 | 54.46 | 40.44 |
| | Distribution | | 0–＜14 yr | 4 (3.7%) | 0 | 4 (4.76%) | | ≥14–＜40 yr | 42 (38.89%) | 2 (8.33%) | 40 (47.61%) | | ≥40–＜65 yr | 48 (44.44%) | 16 (66.67%) | 32 (38.1%) | | ≥65 yr | 14 (12.96%) | 6 (25%) | 8 (9.52%) |
| | Sex | | Male | 56 (51.85%) | 12 (50%) | 44 (52.38%) | | Female | 52 (48.15%) | 12 (50%) | 40 (47.62%) |
| | Wuhan exposure | | Yes | 58 (53.7%) | 16 (66.67%) | 42 (50%) | | No | 50 (46.3%) | 8 (33.33%) | 42 (50%) |
| | Comorbidities | | Yes | 35 (32.41%) | 17 (70.83%) | 18 (21.43%) | | No | 73 (67.59%) | 7 (29.17%) | 66 (78.57%) |
| | Hypertension | 16 (14.81%) | 109 (41.67%) | 6 (7.14%) | | Diabetes | 5 (4.63%) | 2 (8.33%) | 3 (3.57%) | | Cerebral infarction | 4 (3.7%) | 3 (0.125%) | 1 (1.19%) | | Respiratory disease | 3 (2.78%) | 2 (8.33%) | 1 (1.19%) | | Liver disease | 10 (9.26%) | 4 (16.67%) | 6 (7.14%) |
| | Symptoms | | Fever | 73 (67.59%) | 23 (95.83%) | 50 (59.52%) | | Cough | 52 (48.15%) | 13 (54.17%) | 39 (46.43%) | | Pharyngalgia | 15 (13.89%) | 2 (8.33%) | 13 (15.48%) | | Expectoration | 11 (10.19%) | 3 (12.5%) | 9 (10.71%) | | Dyspnea | 8 (7.41%) | 7 (29.17%) | 1 (1.19%) | | Dizziness | 5 (4.63%) | 2 (8.33%) | 3 (3.57%) | | Headache | 4 (3.7%) | 3 (12.5%) | 1 (1.19%) | | Weakness | 40 (37.04%) | 13 (54.17%) | 27 (32.14%) | | Myalgia | 12 (11.11%) | 6 (0.25%) | 6 (7.14%) | | Chills | 10 (9.26%) | 2 (8.33%) | 8 (9.52%) | | Diarrhea | 5 (4.63%) | 3 (12.5%) | 2 (2.38%) |
| Laboratory check (normal value)
White blood cell count (4–10 × 109/L) | | <4 | 39 (36.11%) | 6 (25%) | 33 (39.29%) | | ≥4–＜10 | 65 (60.19%) | 17 (70.83%) | 48 (57.14%) | | ≥10 | 4 (3.7%) | 1 (4.17%) | 3 (3.57%) |
| | Lymphocyte ratio (20–40%) | | <20 | 27 (25%) | 11 (45.83%) | 16 (19.05%) | | ≥20–≤40 | 74 (68.52%) | 13 (54.17%) | 61 (72.62%) | | >40 | 7 (6.48%) | 0 | 7 (8.33%) |
| | Lymphocyte count (0.8–4.0 × 109/L) | | <0.8 | 25 (23.15%) | 11 (45.83%) | 14 (16.67%) | | ≥0.8–≤4.0 | 81 (75%) | 13 (54.17%) | 68 (80.95%) | | >4.0 | 2 (1.85%) | 0 | 2 (2.38%) |
| | CRP (0–8.0 mg/L) | | ≤8 | 32 (29.63%) | 0 | 32 (38.1%) | | >8–≤20 | 26 (24.07%) | 7 (29.17%) | 19 (22.62%) | | >20–≤40 | 29 (26.85%) | 6 (25%) | 23 (27.38%) | | >40 | 21 (19.44%) | 11 (45.83%) | 10 (11.90%) |
| | ESR (0–15 mm/h) | n = 103 | n = 21 | n = 82 | | ≤40 | 54 (52.43%) | 5 (23.81%) | 49 (59.76%) | | >40–≤80 | 39 (37.86%) | 13 (61.9%) | 26 (31.71%) | | >80 | 10 (9.71%) | 3 (14.29%) | 7 (8.54%) |
|
|
